27 results
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
of Lilly, visited POINT’s site in Toronto, Canada, during which representatives of Lilly and POINT toured the POINT Institute for Radioligand Innovation
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
of Lilly, visited POINT’s site in Toronto, Canada, during which representatives of Lilly and POINT toured the POINT Institute for Radioligand Innovation … Innovation.
Marschall S. Runge, M.D., Ph.D.*
Dr. Runge has served as a director of Lilly since 2013. Dr. Runge has served as executive vice president
SC14D9C
EX-99.7
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
5:24pm
agreed to be acquired by Lilly. We are excited to see our pipeline benefit from Lilly’s commitment to oncology, its rich history of innovation and its deep
ARS
a9kr6oh
1 May 23
Annual report to shareholders
1:52pm
424B3
b6cz4tr2m92dimxjodcw
11 Jul 22
Prospectus supplement
4:32pm
POS AM
h28ob56v25jjgqk2105
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
424B3
2fibdr7g
31 Mar 22
Prospectus supplement
11:42am
POS AM
71wjulu4jn3
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
EX-99.1
f6jxlj1nf9ie6l3t 28
25 Feb 22
Prospectus supplement
8:39am
8-K
EX-99.1
ehruu6o m30zn1vgr
25 Feb 22
Regulation FD Disclosure
8:38am
8-K
EX-99.1
jziu imqu
19 Nov 21
Regulation FD Disclosure
8:09am
424B3
dz3o u9wnk8i0ej83
5 Aug 21
Prospectus supplement
4:26pm
S-4/A
EX-10.14
y404vls
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
EX-10.14
7vfg8r1e8s2exos 57
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
425
EX-99.1
eqgfs7fytl0mskwxsnr
15 Mar 21
Business combination disclosure
8:20am
8-K
EX-99.1
vlmygf5
15 Mar 21
Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
8:19am